Tesofensine

Also known as: NS2330

MetabolicPHASE 3

Clinical Status

Phase 3 clinical trials — in development for obesity.

Mechanism of Action

A triple monoamine reuptake inhibitor (serotonin, norepinephrine, and dopamine) that reduces appetite and increases thermogenesis. Originally developed for neurological conditions, repurposed for obesity.

Dosing Defaults

Dose

0.25-0.5 mg

Frequency

1x daily

Administration

Oral

Timing

Morning

Food

with or without

Duration

24 weeks in trials

Dose range: 0.25-1.0 mg daily

Morning dosing avoids insomnia from monoamine reuptake effects.

Side Effects

•Dry mouth
•Insomnia
•Constipation
•Increased heart rate
•Elevated blood pressure
•Mood changes

Contraindications & Warnings

⚠Uncontrolled hypertension
⚠Cardiovascular disease
⚠MAO inhibitor use

•Not medical advice
•Cardiovascular monitoring required

Compare

Compare Tesofensine with another peptide side-by-side.

Calculate Dose

Use the reconstitution calculator to prepare your Tesofensine dose.

Open Calculator

Related Metabolic Peptides

5-Amino-1MQ

PRECLINICAL

Metabolic

NNMT inhibitor that boosts NAD+ for fat metabolism. Does not affect appetite.

AICAR

PHASE 2

Metabolic

AMPK activator known as an "exercise mimetic." Enhances endurance capacity.

Adipotide

PRECLINICAL

Metabolic

Vascular-targeting peptide that destroys blood supply to fat tissue.

Setmelanotide

FDA APPROVED

Metabolic

MC4R agonist for rare genetic obesity. FDA-approved for specific mutations.

This information is for educational purposes only and is not medical advice. Dosing data is based on research literature and community reports. Always consult a qualified healthcare provider before using any peptide.